home / stock / atnm / atnm quote
Last: | $6.96 |
---|---|
Change Percent: | 0.14% |
Open: | $7.19 |
Close: | $6.96 |
High: | $7.31 |
Low: | $6.9 |
Volume: | 181,419 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$6.96 | $7.19 | $6.96 | $7.31 | $6.9 | 181,419 | 07-02-2024 |
$7.2 | $7.28 | $7.2 | $7.375 | $7.05 | 236,292 | 07-01-2024 |
$7.4 | $7.33 | $7.4 | $7.45 | $7.01 | 960,288 | 06-28-2024 |
$7.39 | $7.41 | $7.39 | $7.51 | $7.3 | 97,957 | 06-27-2024 |
$7.37 | $7.15 | $7.37 | $7.43 | $7 | 194,577 | 06-26-2024 |
$7.16 | $7.48 | $7.16 | $7.63 | $7.13 | 246,135 | 06-25-2024 |
$7.48 | $7.34 | $7.48 | $7.67 | $7.33 | 157,561 | 06-24-2024 |
$7.31 | $7.57 | $7.31 | $7.7 | $7.31 | 418,917 | 06-21-2024 |
$7.55 | $7.87 | $7.55 | $7.9365 | $7.55 | 222,379 | 06-20-2024 |
$7.87 | $7.93 | $7.87 | $8.19 | $7.84 | 238,482 | 06-19-2024 |
$7.87 | $7.93 | $7.87 | $8.19 | $7.84 | 238,482 | 06-18-2024 |
$7.93 | $8 | $7.93 | $8.17 | $7.8893 | 243,642 | 06-17-2024 |
$7.82 | $7.95 | $7.82 | $8.09 | $7.75 | 190,219 | 06-14-2024 |
$8.02 | $7.92 | $8.02 | $8.09 | $7.85 | 91,534 | 06-13-2024 |
$7.93 | $8.25 | $7.93 | $8.26 | $7.87 | 181,140 | 06-12-2024 |
$8.08 | $7.86 | $8.08 | $8.205 | $7.85 | 138,843 | 06-11-2024 |
$7.99 | $8 | $7.99 | $8.26 | $7.89 | 188,558 | 06-10-2024 |
$7.96 | $7.92 | $7.96 | $8.14 | $7.875 | 129,183 | 06-07-2024 |
$7.99 | $8.3 | $7.99 | $8.45 | $7.98 | 162,570 | 06-06-2024 |
$8.52 | $8.03 | $8.52 | $8.58 | $7.995 | 167,084 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Actinium Pharmaceuticals Inc. Company Name:
ATNM Stock Symbol:
NYSE Market:
Actinium Pharmaceuticals Inc. Website:
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com , a go-to investing platform covering biotech and medical technology stocks releases the second of a two-part series looking at developments for the treatment of blood cancers, including AML, fe...
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 17, 2024) - Investorideas.com , a go-to investing platform, releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and ...
Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress PR Newswire - Actimab-A enhances dose-depende...